Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA. · 2016
Read Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. by Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5085160.txt.
Description
Eloah Rabello Suarez and seven co-authors engineer immune cells against kidney cancer in Oncotarget in 2016. Clear cell renal cancer resists cure, and T cells sent against it tire out because tumors raise the PD-L1 brake signal. The team built chimeric antigen receptor T cells aimed at a tumor marker, CAIX. They armed them to release anti-PD-L1 antibodies right at the tumor, cutting the brake locally instead of throughout the body.
In a humanized mouse model, the armed cells beat plain CAR T cells clearly: tumor growth fell fivefold and tumor weight dropped by half to four fifths. Tumors showed less PD-L1 and cell division; the T cells carried more granzyme B, and the antibody also drew natural killer cells in. The authors present self-arming CAR T cells as a rescue for this therapy in solid tumors, where it has disappointed.
Catalog record
| CREATOR | Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |